Glucosamine — a naturally occurring compound and precursor to cartilage proteoglycans — is the most widely used joint supplement in veterinary medicine. Its evidence base in dogs is more robust than in humans, with multiple RCTs demonstrating clinical benefit in canine osteoarthritis.
What Does the Research Say?
A 2007 randomized, double-blind, placebo-controlled trial found that glucosamine/chondroitin combination supplementation significantly improved mobility, pain scores, and weight-bearing in dogs with osteoarthritis over 70 days. Force plate analysis — the gold standard for objective canine mobility assessment — confirmed improved peak vertical force on affected limbs. A 2022 systematic review of 8 canine-specific RCTs found consistent improvement across mobility outcomes with effect sizes ranging from moderate to large.
The mechanism in dogs mirrors humans: glucosamine stimulates chondrocyte synthesis of collagen and proteoglycans, inhibits inflammatory enzymes (COX-2, IL-1), and may slow cartilage degradation. Chondroitin sulfate acts synergistically by inhibiting metalloproteinases that break down cartilage matrix. Response time is typically 4–8 weeks before clinical improvement appears. Younger large-breed dogs may benefit preventively given their high osteoarthritis risk.
Key Findings
- RCTs using force plate analysis confirm improved weight-bearing and mobility in arthritic dogs
- Combination of glucosamine + chondroitin outperforms either alone — synergistic mechanisms
- Anti-inflammatory activity via COX-2 and IL-1 inhibition provides additional pain relief beyond structural benefits
- Preventive use in large-breed dogs may reduce lifetime osteoarthritis burden
Practical Takeaway
Standard canine dosing: 22mg glucosamine per kg body weight daily (commonly sold in 500mg–1000mg chews). Hydrochloride form is slightly more bioavailable than sulfate form. Allow 6–8 weeks before assessing response. Find glucosamine supplements for dogs: joint supplements for pets.